Video: Three Myths About Interventional Glaucoma

Zarmeena Vendal, MD, challenges assumptions that interventional glaucoma slows workflow, faces patient resistance, and lacks durability.

By: Zarmeena Vendal, MD

Glaucoma Physician April 10, 2026

5 Key Takeaways

1

Dr. Zarmeena Vendal challenges myths about interventional glaucoma (IG) at the ASCRS 2026 conference.
2

Interventional glaucoma procedures are efficient and do not slow down high-volume surgeons.
3

Patients are receptive to interventional glaucoma technologies, viewing them as opportunities rather than threats.
4

Procedural pharmaceuticals provide better pressure control than traditional eyedrops, offering 24/7 management.
5

The session aimed to encourage practices to adopt interventional glaucoma techniques for improved patient outcomes.

Zarmeena Vendal, MD

Affiliations: Westlake Eye

Bio: Zarmeena Vendal, MD, is a physician at Westlake Eye in Austin, Texas, where she has practiced for 19 years. Her clinical focus includes interventional glaucoma and proactive approaches to glaucoma care. At the Business of Interventional Glaucoma meeting during ASCRS 2026, Dr. Vendal discussed shifting glaucoma treatment earlier, acting ahead of disease progression, and using interventional strategies to reduce treatment burden for patients.

PentaVision

Glaucoma Physician

Video: Three Myths About Interventional Glaucoma

5 Key Takeaways

1

2

3

4

5

Recommendations